{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:51:18Z","timestamp":1793998278523,"version":"4.8.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T00:00:00Z","timestamp":1701820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T00:00:00Z","timestamp":1701820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["NIHR132803"],"award-info":[{"award-number":["NIHR132803"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["NIHR132803"],"award-info":[{"award-number":["NIHR132803"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["NIHR132803"],"award-info":[{"award-number":["NIHR132803"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["NIHR132803"],"award-info":[{"award-number":["NIHR132803"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["NIHR132803"],"award-info":[{"award-number":["NIHR132803"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["NIHR132803"],"award-info":[{"award-number":["NIHR132803"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["NIHR132803"],"award-info":[{"award-number":["NIHR132803"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["NIHR132803"],"award-info":[{"award-number":["NIHR132803"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["NIHR132803"],"award-info":[{"award-number":["NIHR132803"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic migraine can be a profoundly disabling disorder that may be treated with preventive medications. However, uncertainty remains as to which preventive medication is the most effective. We present a network meta-analysis to determine the effectiveness and rank of preventive drugs for chronic migraine in adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We identified, reviewed, and extracted data from randomised controlled trials (RCTs) of preventive drugs for chronic migraine with at least 200 participants. Data were analysed using network meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>We included 12 RCTs of six medications (Eptinezumab, Erenumab, Fremanezumab, Galcanezumab, Onabotulinumtoxin A, and Topiramate) compared to placebo or each other. All drugs effectively reduced monthly headache and migraine days compared with placebo. The most effective drug for monthly headache days was Eptinezumab 300mg, with a mean difference of -2.46 days, 95% Credible Interval (CrI): -3.23 to -1.69. On the Surface Under the Cumulative Ranking Area (SUCRA) analysis, the probability that Eptinezumab 300mg was ranked highest was 0.82. For monthly migraine days, the most effective medication was Fremanezumab-monthly, with a mean difference: -2.77 days, 95% CrI: -3.36 to -2.17, and 0.98 probability of being ranked the highest. All included drugs, except Topiramate, improved headache-related quality of life. No eligible studies were identified for the other common preventive oral medications such as Amitriptyline, Candesartan, and Propranolol. The main reasons were that the studies did not define chronic migraine, were undertaken before the definition of chronic migraine, or were too small.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interpretation<\/jats:title>\n                    <jats:p>All six medications were more effective than the placebo on monthly headache and migraine days. The absolute differences in the number of headache\/migraine days are, at best, modest. No evidence was found to determine the relative effectiveness of the six included drugs with other oral preventive medications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Registration<\/jats:title>\n                    <jats:p>PROSPERO (number CRD42021265990).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s10194-023-01696-w","type":"journal-article","created":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T09:03:35Z","timestamp":1701853415000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Clinical effectiveness of pharmacological interventions for managing chronic migraine in adults: a systematic review and network meta-analysis"],"prefix":"10.1186","volume":"24","author":[{"given":"Seyran","family":"Naghdi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Underwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Madan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Callum","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjit","family":"Matharu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiva","family":"Aksentyte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Rees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Cooklin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Grove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5023-1160","authenticated-orcid":false,"given":"Hema","family":"Mistry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,6]]},"reference":[{"issue":"5","key":"1696_CR1","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/S1474-4422(18)30085-1","volume":"17","author":"J Olesen","year":"2018","unstructured":"Olesen J (2018) International classification of headache disorders. Lancet Neurol 17(5):396\u2013397","journal-title":"Lancet Neurol"},{"issue":"7","key":"1696_CR2","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1177\/0333102411398400","volume":"31","author":"M Lant\u00e9ri-Minet","year":"2011","unstructured":"Lant\u00e9ri-Minet M, Duru G, Mudge M et al (2011) Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: a systematic review. Cephalalgia 31(7):837\u2013850","journal-title":"Cephalalgia"},{"key":"1696_CR3","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s11916-010-0157-z","volume":"15","author":"AN Manack","year":"2011","unstructured":"Manack AN, Buse DC, Lipton RB (2011) Chronic migraine: epidemiology and disease burden. Curr Pain Headache Rep 15:70\u201378","journal-title":"Curr Pain Headache Rep"},{"issue":"10","key":"1696_CR4","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1111\/j.1526-4610.2012.02223.x","volume":"52","author":"DC Buse","year":"2012","unstructured":"Buse DC, Manack AN, Fanning KM et al (2012) Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache 52(10):1456\u201370","journal-title":"Headache"},{"issue":"5","key":"1696_CR5","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/j.1468-2982.2009.01941.x","volume":"30","author":"J Natoli","year":"2010","unstructured":"Natoli J, Manack A, Dean B et al (2010) Global prevalence of chronic migraine: a systematic review. Cephalalgia 30(5):599\u2013609","journal-title":"Cephalalgia"},{"issue":"5","key":"1696_CR6","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/head.13275","volume":"58","author":"M Bonafede","year":"2018","unstructured":"Bonafede M, Sapra S, Shah N et al (2018) Direct and indirect healthcare resource utilization and costs among migraine patients in the United States. Headache 58(5):700\u201314","journal-title":"Headache"},{"issue":"11","key":"1696_CR7","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/S1474-4422(18)30322-3","volume":"17","author":"LJ Stovner","year":"2018","unstructured":"Stovner LJ, Nichols E, Steiner TJ et al (2018) Global, regional, and national burden of migraine and tension-type headache, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology 17(11):954\u2013976","journal-title":"The Lancet Neurology"},{"key":"1696_CR8","unstructured":"The Evidence Centre (2020) The state of the migraine nation: what is the impact of migraine in the UK? Rapid research review London: The Migraine Trust. Available from: https:\/\/migrainetrust.org\/wp-content\/uploads\/2021\/08\/State-of-the-Migraine-Nation-impact-rapid-review.pdf. Accessed 2 May 2023"},{"issue":"1","key":"1696_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-019-1068-y","volume":"20","author":"A Negro","year":"2019","unstructured":"Negro A, Sciattella P, Rossi D et al (2019) Cost of chronic and episodic migraine patients in continuous treatment for two years in a tertiary level headache Centre. J Headache Pain 20(1):1\u201312","journal-title":"J Headache Pain"},{"issue":"4","key":"1696_CR10","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.ncl.2019.06.001","volume":"37","author":"RC Burch","year":"2019","unstructured":"Burch RC, Buse DC, Lipton RB (2019) Migraine: epidemiology, burden, and comorbidity. Neurol Clin 37(4):631\u2013649","journal-title":"Neurol Clin"},{"key":"1696_CR11","unstructured":"National Institute for Health and Care Excellence (NICE) (2021) Headaches in over 12s: diagnosis and management. NICE. https:\/\/www.nice.org.uk\/guidance\/cg150. Accessed 19 Sept 2023."},{"key":"1696_CR12","unstructured":"Scottish Intercollegiate Guidelines Network (SIGN) (2023) Pharmacological management of migraine. Edinburgh: SIGN. https:\/\/www.sign.ac.uk\/our-guidelines\/pharmacological-management-of-migraine\/. Accessed 19 Sept 2023."},{"issue":"1","key":"1696_CR13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1586\/erp.12.78","volume":"13","author":"TJ Steiner","year":"2013","unstructured":"Steiner TJ (2013) Headache in the world: public health and research priorities. Expert Rev Pharmacoecon Outcomes Res 13(1):51\u201357","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"7","key":"1696_CR14","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/head.14153","volume":"61","author":"J Ailani","year":"2021","unstructured":"Ailani J, Burch RC, Robbins MS et al (2021) The American Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice. Headache 61(7):1021\u201339","journal-title":"Headache"},{"key":"1696_CR15","unstructured":"National Institute for Health and Care Excellence (NICE) (2012) Botulinum toxin type A for the prevention of headaches in adults with chronic migraine. NICE. Accessed 19 Sept 2023."},{"issue":"8","key":"1696_CR16","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1080\/03007995.2022.2091333","volume":"38","author":"OJ Varnado","year":"2022","unstructured":"Varnado OJ, Hoyt M, Ye W et al (2022) Patient characteristics and treatment utilization among patients with migraine initiating self-injectable calcitonin gene-related peptide monoclonal antibody and novel acute medication. Curr Med Res Opin 38(8):1451\u20131457","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"1696_CR17","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/ane.13391","volume":"143","author":"H Zheng","year":"2021","unstructured":"Zheng H, Huang SL, Chen YY et al (2021) Topiramate, acupuncture, and BoNT-A for chronic migraine: a network meta-analysis. Acta Neurol Scand 143(5):558\u2013568","journal-title":"Acta Neurol Scand"},{"key":"1696_CR18","doi-asserted-by":"publisher","first-page":"n160","DOI":"10.1136\/bmj.n160","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM et al (2021) PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 372:n160","journal-title":"BMJ."},{"key":"1696_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"JP Higgins","year":"2019","unstructured":"Higgins JP, Thomas J, Chandler J et al (2019) Cochrane handbook for systematic reviews of interventions, 2nd edn. Chichester, Wiley","edition":"2"},{"key":"1696_CR20","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1007\/s11136-012-0230-7","volume":"22","author":"R Rendas-Baum","year":"2013","unstructured":"Rendas-Baum R, Bloudek LM, Maglinte GA et al (2013) The psychometric properties of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ) in chronic migraine patients. Qual Life Res 22:1123\u201333","journal-title":"Qual Life Res"},{"key":"1696_CR21","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s11136-020-02688-y","volume":"30","author":"Y-S Feng","year":"2021","unstructured":"Feng Y-S, Kohlmann T, Janssen MF et al (2021) Psychometric properties of the EQ-5D-5L: a systematic review of the literature. Qual Life Res 30:647\u2013673","journal-title":"Qual Life Res"},{"issue":"3","key":"1696_CR22","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1177\/0333102410379890","volume":"31","author":"M Yang","year":"2011","unstructured":"Yang M, Rendas-Baum R, Varon SF et al (2011) Validation of the Headache Impact Test (HIT-6\u2122) across episodic and chronic migraine. Cephalalgia 31(3):357\u2013367","journal-title":"Cephalalgia"},{"key":"1696_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1745-6215-8-31","volume":"8","author":"SM Snapinn","year":"2007","unstructured":"Snapinn SM, Jiang Q (2007) Responder analyses and the assessment of a clinically relevant treatment effect. Trials 8:1\u20136","journal-title":"Trials"},{"issue":"2","key":"1696_CR24","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1002\/pst.2273","volume":"22","author":"R Abugov","year":"2023","unstructured":"Abugov R, Clark J, Higginbotham L et al (2023) Should responder analyses be conducted on continuous outcomes? Pharm Stat 22(2):312\u2013327","journal-title":"Pharm Stat"},{"key":"1696_CR25","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jclinepi.2021.01.026","volume":"134","author":"D Collister","year":"2021","unstructured":"Collister D, Bangdiwala S, Walsh M et al (2021) Patient reported outcome measures in clinical trials should be initially analyzed as continuous outcomes for statistical significance and responder analyses should be reserved as secondary analyses. J Clin Epidemiol 134:95\u2013102","journal-title":"J Clin Epidemiol"},{"key":"1696_CR26","unstructured":"StataCorp. Stata Statistical Software: Release 17. College Station, TX: StataCorp LLC; 2021."},{"key":"1696_CR27","doi-asserted-by":"crossref","unstructured":"Phillippo DM. Multinma: An R package for Bayesian network meta-analysis of individual and aggregate data: version 4.1.3. 2021.","DOI":"10.32614\/CRAN.package.multinma"},{"key":"1696_CR28","unstructured":"R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2021."},{"issue":"6","key":"1696_CR29","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1111\/jce.14490","volume":"31","author":"GC Fernandes","year":"2020","unstructured":"Fernandes GC, Knijnik L, Lopez J et al (2020) Network meta-analysis of His bundle, biventricular, or right ventricular pacing as a primary strategy for advanced atrioventricular conduction disease with normal or mildly reduced ejection fraction. J Cardiovasc Electrophysiol 31(6):1482\u20131492","journal-title":"J Cardiovasc Electrophysiol"},{"key":"1696_CR30","doi-asserted-by":"crossref","unstructured":"Page MJ, Higgins JP, Sterne JA (2019) Assessing risk of bias due to missing results in a synthesis. Cochrane handbook Syst Rev Interv\u00a0349\u201374","DOI":"10.1002\/9781119536604.ch13"},{"key":"1696_CR31","doi-asserted-by":"crossref","unstructured":"Phillips M (2021) Healthcare Recommendations: Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) Approach. Evid Based Orthop\u00a019\u201323","DOI":"10.1002\/9781119413936.ch4"},{"issue":"24","key":"1696_CR32","doi-asserted-by":"publisher","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","volume":"91","author":"HC Detke","year":"2018","unstructured":"Detke HC, Goadsby PJ, Wang S et al (2018) Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology 91(24):e2211\u2013e2221","journal-title":"Neurology"},{"issue":"10","key":"1696_CR33","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1111\/j.1526-4610.2007.00950.x","volume":"47","author":"DW Dodick","year":"2007","unstructured":"Dodick DW, Silberstein S, Saper J et al (2007) The impact of topiramate on health-related quality of life indicators in chronic migraine. Headache 47(10):1398\u2013408","journal-title":"Headache"},{"issue":"22","key":"1696_CR34","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","volume":"377","author":"SD Silberstein","year":"2017","unstructured":"Silberstein SD, Dodick DW, Bigal ME et al (2017) Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med 377(22):2113\u20132122","journal-title":"N Engl J Med"},{"issue":"7","key":"1696_CR35","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1111\/head.14169","volume":"61","author":"F Sakai","year":"2021","unstructured":"Sakai F, Suzuki N, Kim BK et al (2021) Efficacy and safety of fremanezumab for chronic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients. Headache 61(7):1092\u2013101","journal-title":"Headache"},{"issue":"7","key":"1696_CR36","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1177\/0333102410364676","volume":"30","author":"S Aurora","year":"2010","unstructured":"Aurora S, Dodick D, Turkel C et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 30(7):793\u2013803","journal-title":"Cephalalgia"},{"issue":"7","key":"1696_CR37","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1177\/0333102410364677","volume":"30","author":"H Diener","year":"2010","unstructured":"Diener H, Dodick D, Aurora S et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 30(7):804\u2013814","journal-title":"Cephalalgia"},{"issue":"13","key":"1696_CR38","doi-asserted-by":"publisher","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","volume":"94","author":"RB Lipton","year":"2020","unstructured":"Lipton RB, Goadsby PJ, Smith J et al (2020) Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology 94(13):e1365\u2013e1377","journal-title":"Neurology"},{"issue":"9","key":"1696_CR39","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1177\/0333102419858355","volume":"39","author":"DW Dodick","year":"2019","unstructured":"Dodick DW, Lipton RB, Silberstein S et al (2019) Eptinezumab for prevention of chronic migraine: a randomized phase 2b clinical trial. Cephalalgia 39(9):1075\u20131085","journal-title":"Cephalalgia"},{"issue":"6","key":"1696_CR40","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","volume":"16","author":"S Tepper","year":"2017","unstructured":"Tepper S, Ashina M, Reuter U et al (2017) Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 16(6):425\u2013434","journal-title":"Lancet Neurol"},{"issue":"10","key":"1696_CR41","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1111\/head.13653","volume":"59","author":"JF Rothrock","year":"2019","unstructured":"Rothrock JF, Adams AM, Lipton RB et al (2019) FORWARD study: evaluating the comparative effectiveness of onabotulinumtoxinA and topiramate for headache prevention in adults with chronic migraine. Headache 59(10):1700\u201313","journal-title":"Headache"},{"issue":"10203","key":"1696_CR42","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","volume":"394","author":"MD Ferrari","year":"2019","unstructured":"Ferrari MD, Diener HC, Ning X et al (2019) Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet 394(10203):1030\u20131040","journal-title":"Lancet"},{"issue":"1","key":"1696_CR43","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s10194-022-01514-9","volume":"23","author":"S Yu","year":"2022","unstructured":"Yu S, Kim B-K, Wang H et al (2022) A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study. J Headache Pain 23(1):146","journal-title":"J Headache Pain"},{"issue":"2","key":"1696_CR44","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/j.1526-4610.2006.00684.x","volume":"47","author":"SD Silberstein","year":"2007","unstructured":"Silberstein SD, Lipton RB, Dodick DW et al (2007) Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 47(2):170\u201380","journal-title":"Headache"},{"issue":"8","key":"1696_CR45","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1111\/j.1526-4610.2009.01508.x","volume":"49","author":"S Silberstein","year":"2009","unstructured":"Silberstein S, Lipton R, Dodick D et al (2009) Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures. Headache 49(8):1153\u201362","journal-title":"Headache"},{"issue":"9","key":"1696_CR46","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1177\/0333102416652092","volume":"36","author":"RB Lipton","year":"2016","unstructured":"Lipton RB, Rosen NL, Ailani J et al (2016) OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: pooled results from the PREEMPT randomized clinical trial program. Cephalalgia 36(9):899\u2013908","journal-title":"Cephalalgia"},{"issue":"1","key":"1696_CR47","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s11136-020-02623-1","volume":"30","author":"J Ford","year":"2021","unstructured":"Ford J, Tassorelli C, Leroux E et al (2021) Changes in patient functioning and disability: results from a phase 3, double-blind, randomized, placebo-controlled clinical trial evaluating galcanezumab for chronic migraine prevention (REGAIN). Qual Life Res 30(1):105\u2013115","journal-title":"Qual Life Res"},{"issue":"7","key":"1696_CR48","doi-asserted-by":"publisher","first-page":"e878","DOI":"10.1212\/WNL.0000000000010000","volume":"95","author":"RB Lipton","year":"2020","unstructured":"Lipton RB, Cohen JM, Gandhi SK et al (2020) Effect of fremanezumab on quality of life and productivity in patients with chronic migraine. Neurology 95(7):e878\u2013e888","journal-title":"Neurology"},{"issue":"19","key":"1696_CR49","doi-asserted-by":"publisher","first-page":"e2250","DOI":"10.1212\/WNL.0000000000007452","volume":"92","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, Tepper SJ, Reuter U et al (2019) Erenumab in chronic migraine: patient-reported outcomes in a randomized double-blind study. Neurology 92(19):e2250\u2013e2260","journal-title":"Neurology"},{"issue":"1","key":"1696_CR50","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/head.14036","volume":"61","author":"HC Diener","year":"2021","unstructured":"Diener HC, Marmura MJ, Tepper SJ et al (2021) Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: subgroup analysis of PROMISE-2. Headache 61(1):125\u201336","journal-title":"Headache"},{"issue":"19","key":"1696_CR51","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1001\/jama.2018.4853","volume":"319","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Silberstein SD, Bigal ME et al (2018) Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA 319(19):1999\u20132008","journal-title":"JAMA"},{"key":"1696_CR52","doi-asserted-by":"publisher","first-page":"106893","DOI":"10.1016\/j.clineuro.2021.106893","volume":"209","author":"P Soni","year":"2021","unstructured":"Soni P, Chawla E (2021) Efficacy and safety of anti-calcitonin gene-related peptide monoclonal antibodies for treatment of chronic migraine: a systematic review and network meta-analysis. Clin Neurol Neurosurg 209:106893","journal-title":"Clin Neurol Neurosurg"},{"key":"1696_CR53","doi-asserted-by":"crossref","unstructured":"Mahon R, Vo P, Pannagl K, et al (2023) Assessment of the relative effectiveness of erenumab compared with onabotulinumtoxinA for the prevention of chronic migraine. Curr Med Res Opin 39(1):105\u2013112.","DOI":"10.1080\/03007995.2022.2131299"},{"key":"1696_CR54","doi-asserted-by":"publisher","first-page":"649143","DOI":"10.3389\/fphar.2021.649143","volume":"12","author":"X Wang","year":"2021","unstructured":"Wang X, Chen Y, Song J et al (2021) Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine: a systematic review and network meta-analysis. Front Pharmacol 12:649143","journal-title":"Front Pharmacol"},{"issue":"13","key":"1696_CR55","doi-asserted-by":"publisher","first-page":"e1339","DOI":"10.1212\/WNL.0000000000201518","volume":"100","author":"M Underwood","year":"2023","unstructured":"Underwood M, Achana F, Carnes D et al (2023) Supportive self-management program for people with chronic headaches and migraine: a randomized controlled trial and economic evaluation. Neurology 100(13):e1339\u2013e1352","journal-title":"Neurology"},{"issue":"1","key":"1696_CR56","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s10194-022-01492-y","volume":"23","author":"S Khanal","year":"2022","unstructured":"Khanal S, Underwood M, Naghdi S et al (2022) A systematic review of economic evaluations of pharmacological treatments for adults with chronic migraine. J Headache Pain 23(1):122","journal-title":"J Headache Pain"},{"issue":"11","key":"1696_CR57","doi-asserted-by":"publisher","first-page":"e043242","DOI":"10.1136\/bmjopen-2020-043242","volume":"11","author":"K Haywood","year":"2021","unstructured":"Haywood K, Potter R, Froud R et al (2021) Core outcome set for preventive intervention trials in chronic and episodic migraine (COSMIG): an international, consensus-derived and multistakeholder initiative. BMJ Open 11(11):e043242","journal-title":"BMJ Open"},{"issue":"13","key":"1696_CR58","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1212\/WNL.0b013e31824d5846","volume":"78","author":"S Silberstein","year":"2012","unstructured":"Silberstein S, Dodick D, Lindblad A et al (2012) Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine. Neurology 78(13):976\u2013984","journal-title":"Neurology"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01696-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-023-01696-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01696-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T03:44:47Z","timestamp":1730778287000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-023-01696-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,6]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1696"],"URL":"https:\/\/doi.org\/10.1186\/s10194-023-01696-w","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,6]]},"assertion":[{"value":"12 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Martin Underwood is chief investigator or co-investigator on multiple previous and current research grants from the UK National Institute for Health Research and is a co-investigator on grants funded by the Australian NHMRC and Norwegian MRC. He was an NIHR Senior Investigator until March 2021. He is a director and shareholder of Clinvivo Ltd, which provides electronic data collection for health services research. He is part of an academic partnership with Serco Ltd, funded by the European Social Fund, related to return-to-work initiatives. He receives some salary support from University Hospitals Coventry and Warwickshire. He is a co-investigator on two current and one completed NIHR-funded studies that have, or have had, additional support from Stryker Ltd.Amy Grove is a member of the NIHR HTA Commissioning Committee and a member of the NIHR DSE Fellowship Funding Committee.Callum Duncan is chair of Scottish Intercollegiate Guideline Network (SIGN) 155 and has provided advice on the use of Botox, CGRP monoclonal antibodies and CGRP antagonists to the Scottish Medicines Consortium and on Eptinezumab to NICE. He was the Secretary for the British Association for the Study of Headache 2015\u20132022 and is a Board member of Anglo Dutch Migraine Association.Manjit Matharu is the President of the medical advisory board of the CSF Leak Association. He has received consulting fees from AbbVie, TEVA, Lundbeck, Eli Lilly, Salvia, and Pfizer. He has received payment for the development of educational presentations from AbbVie, Pfizer and Eli Lilly and support for attending a meeting from Pfizer. He is on the advisory board for AbbVie, TEVA, Lunbeck, Eli Lilly, Salvia and Pfizer. He has the following patent issued WO2018051103A1: System and method for diagnosing and treating headaches. He has stock options with Tesla, Adobe, Nvidia, META, and Microsoft. He has received grants from Abbott, Medtronic and Ehlers Danlos society.Hema Mistry is a member of the NIHR HTA General Funding Commissioning Committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"164"}}